Welcome to our dedicated page for NOVONIX SEC filings (Ticker: NVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NOVONIX Limited filings document foreign-issuer reporting for an ADR-listed battery materials and technology company. Its Form 6-K reports furnish ASX announcements, operating and financial results, material-event disclosures, material agreements, shareholder voting matters, and governance updates.
Company filings also record capital-structure activity such as applications for quotation of ordinary fully paid shares, notifications of unquoted equity securities, employee incentive performance rights, and director interest notices. These disclosures connect NOVONIX's public reporting with its ordinary shares, American depositary shares, incentive securities, and governance obligations as an Australian issuer with U.S. reporting.
NOVONIX Limited reported a key operational milestone, delivering a mass production qualification “C-sample” of synthetic graphite anode active material to its lead customer, Panasonic Energy. The company says internal testing shows the material meets Panasonic’s required specifications, while formal validation will depend on Panasonic’s assessment in the coming months.
The delivery is described as the first known Synthetic Graphite AAM C-sample produced in North America and is framed as an important step toward a secure U.S. battery materials supply chain. NOVONIX also reaffirmed its expectation that mass production for Panasonic will begin in the second half of 2027, subject to successful completion of qualification by Panasonic and its customers.
NOVONIX Limited reports a leadership transition in its finance team. Chief Financial Officer Robert Long will leave the company in July to pursue other opportunities. Current Chair Ron Edmonds, a veteran finance leader formerly with Dow Chemical, will serve as Interim Chief Financial Officer and step aside as Chair during the search for a permanent replacement. Deputy Chair Admiral Robert Natter will take over as Chair so Edmonds can focus on the interim CFO role. The Board states it is confident these arrangements will maintain leadership continuity and support ongoing operations while a new full-time CFO is recruited.
NOVONIX Ltd Chief Operating Officer Dwayne Arnold Johnson reported six Form 4 transactions involving performance rights linked to ordinary shares. All are coded as “other acquisition or disposition” (code J) and classified as restructuring transactions covering an aggregate 2,932,881 performance rights at an exercise price of $0.0000 per right. No shares were reported as bought or sold, and the transaction summary shows zero net buy or sell activity.
NOVONIX LIMITED reported that 2,932,881 unquoted NVXAD performance rights have lapsed because the performance conditions were not met or can no longer be satisfied. No consideration was paid for this cessation.
After this change, the company has 862,227,757 ordinary fully paid shares on issue, alongside remaining unquoted performance rights, options, share rights and convertible notes.
NOVONIX Limited has applied to quote 784,817 new ordinary fully paid shares on the ASX, issued on 13 May 2026 after the conversion of performance rights under an employee incentive scheme. These additional shares form part of the existing NVX ordinary share class and rank equally with existing shares.
The shares are being issued for non‑cash consideration, with an estimated value of AUD 0.235 per security. After this quotation, the company reports a total of 862,227,757 NVX ordinary fully paid shares on issue, alongside several classes of unquoted performance rights, options, share rights, convertible notes and convertible debentures.
NOVONIX Ltd director Robert J. Natter reported internal transfers of company shares between accounts he beneficially owns. On the reported date, three “J” code transactions moved a total of 460,686 ordinary shares among direct holdings and family trusts at a stated price of $0.0000 per share.
A footnote explains these were administrative transfers and did not change his overall economic interest in NOVONIX securities. He also holds share rights over 195,938 underlying ordinary shares with a stated exercise price of $0.0000 and an expiration date of December 31, 2027.
NOVONIX Ltd director Tony Bellas reported his derivative holdings of share rights linked to ordinary shares. The filing shows 195,938 underlying ordinary shares tied to these share rights at an exercise price of $0.0000 per share, exercisable from December 31, 2026 and expiring on December 31, 2027. No purchases or sales were reported; this entry updates his position in these rights.
NOVONIX Ltd director Jean Oelwang reported a derivative holding of 195,938 share rights linked to ordinary shares. These share rights have an exercise price of $0.0000 and are scheduled to expire on December 31, 2027. The filing shows 195,938 underlying ordinary shares associated with this position, with no buy or sell transactions indicated in the provided data.
NOVONIX Ltd director Ronald C. Edmonds reported his holdings of share rights linked to the company’s ordinary shares. The filing shows share rights over 195,938 underlying ordinary shares with an exercise price of $0.00 per share, exercisable from December 31, 2026 and expiring on December 31, 2027. This entry reflects a reported position rather than a new purchase or sale.
NOVONIX Ltd director Burrow Sharan reported a holding of 195,938 share rights linked to ordinary shares. These rights have a zero exercise price and are scheduled to become exercisable on December 31, 2026, with an expiration date of December 31, 2027. The filing reflects a position update rather than a new buy or sell transaction.